

<https://helda.helsinki.fi>

Puumala Hantavirus Infections Show Extensive Variation in Clinical Outcome

Vaheri, Antti

Multidisciplinary Digital Publishing Institute

2023-03-22

Vaheri, A.; Smura, T.; Vauhkonen, H.; Hepojoki, J.; Sironen, T.; Strandin, T.; Tietäväinen, J.; Outinen, T.; Mäkelä, S.; Pörsti, I.; Mustonen, J. Puumala Hantavirus Infections Show Extensive Variation in Clinical Outcome. *Viruses* 2023, 15, 805.

<http://hdl.handle.net/10138/356617>

Downloaded from Helda, University of Helsinki institutional repository.








This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

Opinion

Puumala Hantavirus Infections Show Extensive Variation in Clinical Outcome

Antti Vaeheri ^{1,*}, Teemu Smura ¹, Hanna Vauhkonen ¹, Jussi Hepojoki ¹, Tarja Sironen ¹, Tomas Strandin ¹,
Johanna Tietäväinen ^{2,3}, Tuula Outinen ³, Satu Mäkelä ³, Ilkka Pörsti ^{2,3} and Jukka Mustonen ^{2,3}

¹ Department of Virology, Medicum, University of Helsinki, 00290 Helsinki, Finland

² Faculty of Medicine and Health Technology, Tampere University, 33014 Tampere, Finland

³ Department of Internal Medicine, Tampere University Hospital, 33520 Tampere, Finland

* Correspondence: antti.vaeheri@helsinki.fi; Tel.: +358-505552884

Abstract: The clinical outcome of Puumala hantavirus (PUUV) infection shows extensive variation, ranging from inapparent subclinical infection (70–80%) to severe hemorrhagic fever with renal syndrome (HFRS), with about 0.1% of cases being fatal. Most hospitalized patients experience acute kidney injury (AKI), histologically known as acute hemorrhagic tubulointerstitial nephritis. Why this variation? There is no evidence that there would be more virulent and less virulent variants infecting humans, although this has not been extensively studied. Individuals with the human leukocyte antigen (HLA) alleles B*08 and DRB1*0301 are likely to have a severe form of the PUUV infection, and those with B*27 are likely to have a benign clinical course. Other genetic factors, related to the tumor necrosis factor (TNF) gene and the C4A component of the complement system, may be involved. Various autoimmune phenomena and Epstein-Barr virus infection are associated with PUUV infection, but hantavirus-neutralizing antibodies are not associated with lower disease severity in PUUV HFRS. Wide individual differences occur in ocular and central nervous system (CNS) manifestations and in the long-term consequences of nephropathia epidemica (NE). Numerous biomarkers have been detected, and some are clinically used to assess and predict the severity of PUUV infection. A new addition is the plasma glucose concentration associated with the severity of both capillary leakage, thrombocytopenia, inflammation, and AKI in PUUV infection. Our question, “Why this variation?” remains largely unanswered.

Keywords: orthohantavirus; hemorrhagic fever with renal syndrome; HLA; nephropathia epidemica; Puumala hantavirus; biomarker



Citation: Vaeheri, A.; Smura, T.; Vauhkonen, H.; Hepojoki, J.; Sironen, T.; Strandin, T.; Tietäväinen, J.; Outinen, T.; Mäkelä, S.; Pörsti, I.; et al. Puumala Hantavirus Infections Show Extensive Variation in Clinical Outcome. *Viruses* **2023**, *15*, 805. <https://doi.org/10.3390/v15030805>

Academic Editors: Colleen B. Jonsson, Connie Schmaljohn, Misa Korva and Jin-Won Song

Received: 27 February 2023
Revised: 17 March 2023
Accepted: 20 March 2023
Published: 22 March 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Puumala orthohantavirus (PUUV) is an enveloped virus with a tri-segmented negative-strand RNA genome. PUUV is one of the many human-pathogenic members of the *Orthohantavirus* genus. However, in the following, we refer to them using the simple designation “hantaviruses”. They are currently classified into two categories: viruses causing hemorrhagic fever with renal syndrome (HFRS) and viruses causing hantavirus cardiopulmonary syndrome (HCPS), although hemorrhages also occur in HCPS and the heart and lungs are also affected in HFRS. PUUV is the only hantaviral human pathogen in Finland, a country with globally the highest incidence of hantavirus infections and a significant impact on public health. Nephropathia epidemica (NE), caused by PUUV, is also common in Northern Sweden and parts of Central and Eastern Europe [1–3].

In PUUV-caused NE, the clinical picture is dominated by acute kidney injury (AKI), which is histologically characterized by acute hemorrhagic tubulointerstitial nephritis. Most of the hospitalized NE patients have AKI, and up to 6% of them require transient dialysis treatment [4]. The case fatality rate is very low, ranging from 0.08% to 0.4% [1–3].

The reported average incidence of diagnosed PUUV infections in Finland is 31 to 39 cases per 100,000 inhabitants. From the seroprevalence up to 12.5% in the adult population

and the incidence of NE in some areas of Finland, it has been estimated that only 20–30% of infected humans seek medical attention, leading to serological confirmation [1–3]. This wide range of clinical outcomes and the large proportion of subclinical cases are a unique feature of human-pathogenic hantaviruses, both among those causing HFRS and HCPS. In the following, we will consider what might lie behind this characteristic of PUUV infection. Is it in the virus or in its human host?

2. Role of Different Factors in the Variation

2.1. Hantavirus Virulence

The clinical course of human hantavirus infections varies greatly according to the different hantaviruses, ranging from no disease to a mild course with a low case-fatality rate (about 0.1% in PUUV infection) to a severe course up to 40%–50% in Sin Nombre (SNV) and Andes (ANDV) virus infections [2,5].

Genetically and antigenically related hantaviruses can show large differences in virulence. Currently, the Dobrava-Belgrade orthohantavirus species is divided into four distinct European hantavirus genotypes: Dobrava (DOBV), Kurkino (KURV), Saaremaa (SAAV), and Sochi (SOCV) viruses [6]. These genotypes correspond to different phylogenetic lineages and display specific host reservoirs, geographical distribution, and pathogenicity for suckling mice and humans [7]. More detailed studies of these closely related hantavirus genotypes, causing either life-threatening infections (DOBV and SOCV), relatively mild infections (KURV), or possibly only subclinical human infections (SAAV), could reveal the genetic determinants of virus-host interaction mechanisms leading to virulence.

PUUV infection in the reservoir host, the bank vole (*Myodes glareolus*), is subclinical and persistent, with prolonged viremia and virus shedding in saliva and feces [1,8]. The human infection, obtained by inhalation of aerosolized rodent excreta, presents as NE, with varying severity. Experiments in a nonhuman primate (macaque) model of inhalational SARS-CoV-2 virus infection [9] suggest that a large infectious dose may lead to a more severe virus infection. In these experiments, however, the symptoms (fever) developed in less than two days, in contrast to intravenous PUUV infection in macaques, where the first symptoms (loss of appetite) appeared only after a week [10]. Natural human PUUV infection through inhalation of aerosolized rodent excreta has an incubation time of 2–4 weeks [1–4].

PUUV, as a tri-segmented negative-strand RNA virus, shows rapid genetic microevolution both in vivo in the bank vole and in cell culture, e.g., [11,12]. However, there is no evidence that there would be more virulent and less virulent variants infecting humans [1–4]. Thus, we propose that the reason for the extensive individual differences in the clinical outcome of PUUV infection resides, at least mainly, in the human host.

2.2. Human Genetic Factors and Immunity in the Pathogenesis of PUUV Infection

Immunogenetic investigations have mainly focused on the human leukocyte antigen (HLA) system and genes that encode molecules associated with this complex, such as the C4A component of the complement system. Many associations between alleles, or combinations of alleles, and susceptibility to infectious and autoimmune diseases have been described in humans [13].

In Finland, the individuals with HLA alleles HLA-B*08 and DRB1*0301 are likely to have the most severe form of the PUUV infection with lower blood pressures, higher creatinine [14,15], and more virus excretion into the urine and the blood [15]. On the contrary, individuals with HLA-B*27 have a benign clinical course [16]. In Slovenia, the HLA-DRB1*15 haplotype was more frequent in patients with severe PUUV-HFRS progression than in patients with a mild course of the disease [17]. Similarly, distinct HLA haplotypes are associated with severe Hantaan virus (HTNV) HFRS, severe Sin Nombre (SNV) HCPS, severe Andes virus (ANDV) HCPS, and mild ANDV HCPS [7].

The tumor necrosis factor (TNF) cluster belongs to the class III region of the HLA system [18]. The -G308A SNP in the promoter region of this gene correlates with the severe

clinical course of PUUV infection in Finnish patients [19] and is strongly expressed in the kidneys of PUUV-infected humans [20]. The TNF gene is partly involved in severe PUUV disease but is a less important risk factor than the HLA-B*08–HLA-DRB1*0301 haplotype [21].

There is indirect evidence [22] that HLA molecules could act as coreceptors for viruses, but curiously, this potentially important finding has not been confirmed or extended to viruses other than human coronavirus OC43 (HCoV-OC43), which causes the common cold in humans. This report [22] was based on the use of monoclonal antibodies to HLA-A, -B, and -C specificities for blocking HCoV-OC43 infectivity in human rhabdomyosarcoma (RD) cells, transfection of HLA-A3.1 to human plasma cells, and immunoprecipitation with polyclonal antiviral antibodies.

Notably, the PUUV infection risk haplotype HLA-B*08–HLA-DRB1*0301 invariably carries a deletion of the C4A gene encoding the C4A component of the complement system [23], which is important in the pathogenesis of PUUV infection. In addition to vascular leakage, excessive complement activation is in fact a major feature of severe and lethal NE [24–26].

Abnormal chest radiographic findings are common in acute PUUV infection. We have found that also the presence and severity of abnormal findings associate with HLA-B*08–HLA-DRB1*0301 and TNF2 alleles [27]. Pleural effusion, as a sign of increased capillary permeability, showed the strongest association with these genetic factors.

Polymorphism of certain cytokine genes may contribute to susceptibility to PUUV infection [28]. Polymorphisms of plasminogen activator inhibitor (PAI-1) and platelet glycoprotein (GP) associate with the severity of AKI and thrombocytopenia [29], and the endothelial nitric oxide synthase G894T polymorphism with the severity of AKI and hypotension [30].

The special nature of PUUV infection may also be evident in the fact that, unlike in HCPS caused by SNV [31], hantavirus-neutralizing antibodies do not associate with lower disease severity in PUUV HFRS [32].

PUUV infection does not cause direct cytopathology (cell death) or apoptosis but induces a vigorous immune response, mediated by both B-cells and T-cells. The PUUV infection has been associated with many autoimmune phenomena and the Epstein-Barr virus (EBV) infection. In early studies [33] we found rheumatoid factors, recognized in viral illnesses, circulating immune complexes, and increased levels of IgM in all 18 patients with PUUV-induced disease; the levels of IgG and IgA increased during the clinical disease but remained normal. We also found anti-endothelial cell antibodies in NE and other viral diseases [34]. We detected autoimmune polyendocrinopathy and hypophysitis after PUUV infection [35]. Human CD8 T-cell response in PUUV infection occurs after the acute phase and, curiously, is associated with boosting of EBV-specific CD8 memory T-cells and transient presence of EBV DNA in some patients, indicative of viral reactivation [36]. These findings may be because EBV is a polyclonal B-cell activator and can also explain the following findings in PUUV infection: nonrelated toxoid immunity in PUUV infection (tetanus-specific and pertussis-specific IgG as well as T-cells) [37], the free immunoglobulin light chains in hantavirus infection [38], and the observed [39] increased risk (73%) for lymphoma (resembling mononucleosis-associated Hodgkin lymphoma) after PUUV HFRS.

Ocular and CNS manifestations in PUUV hantavirus infections show wide individual differences in symptoms such as transient myopia, acute glaucoma, uveitis, headache, nausea/vomiting, dizziness, and PUUV-induced encephalitis [40–47]. A genetic susceptibility to PUUV encephalitis has been suggested in a recent study by Partanen et al. [47]. They found a variant in the toll-like receptor 3 (TLR3) gene that led to compromised receptor activity and abnormal interferon activity. This variant is enriched in the Finnish population, and it is possible that PUUV encephalitis is more common in Finland than in other populations [47]. Hormonal defects are common during PUUV infection and are associated with disease severity and biomarkers of altered hemostasis [48–50].

The clinical course of PUUV infection seems to be less severe in children than in adults [51]. The same conclusion was made in a systematic literature review that included 53 published studies. Children with PUUV infections rarely, if ever, need any invasive therapy such as acute dialysis or respiratory support [52]. No significant differences in the clinical severity of NE were observed between HLA-B*08 and HLA-DRB1*0301 positives and negatives [53]. An explanation could be the mild course of the disease in children.

In a Chinese study, it was found that although the incidence of HFRS was higher for males, the incidence of the case fatality rate was slightly higher among females of certain age groups [54]. However, a German study showed that there are no sex-related differences in the severity of PUUV infection [55].

ABO and rhesus blood groups have been reported to affect the risk of COVID-19, hepatitis B, norovirus, and possibly HIV infection. According to our study [56], patients with blood group O may be less susceptible to hypotension, but otherwise, blood groups have no major influences on disease susceptibility or severity during acute PUUV infection.

2.3. External Factors and Other Viral Genes Affecting PUUV Infection

In our series of 116 patients with an acute PUUV infection, seroconversion occurred against the Ljungan and lymphocytic choriomeningitis viruses (LCMV), and orthopoxviruses in some patients [57]. Cases with LCMV seroconversions were statistically younger, had milder AKI, and had more severe thrombocytopenia than patients without LCMV. However, the low number of seroconversion cases precludes drawing firm conclusions. Due to the low number of cases, further studies are needed to find out if co-infections with other rodent-borne viruses really have an influence on the clinical picture of PUUV infection.

Smoking is a known risk factor for PUUV infection [58–60]. In a large series of NE patients, we have shown that smoking is common in hospital-treated patients and that current smokers suffer from more severe AKI and inflammation than ex-smokers or never-smokers [58]. The putative mechanistic details of the enhanced pathogenesis need further study. Recently, we reported that the alcohol consumption of the patients did not seem to affect the clinical course of acute PUUV infection [61].

The possibility that (re)activation of other viral genes (such as those of chronic infections or integrated viral genomes) affects the clinical outcome of PUUV infection deserves to be studied.

*2.4. Biomarkers Predicting the Outcome of PUUV Infection, *cr**

We have detected and evaluated numerous biomarkers in PUUV HFRS (NE), as recently reviewed [62]. This has been performed with two aims: (i) to understand better the pathogenesis of NE [4] and (ii) to use the biomarkers to predict the disease severity and long-term consequences of the disease [63–66]. As summarized in our recent review [67], cardiovascular, nephrological, and endocrinological consequences have been found in some patients, but severe complications are rare.

The list of biomarkers evaluated is long: interleukin-6, C-reactive protein (CRP), pentraxin-3, indoleamine 2-3-dioxygenase, cell-free DNA, soluble urokinase-type plasminogen activator, resistin, YKL-40, galectin-3 binding protein (Gal-3BP; Mac-2 binding protein), GATA-3, neutrophil gelatinase-associated lipocalin (NGAL), and procalcitonin [62].

In clinical practice, however, only thrombocytopenia, low blood pressure, creatinine, and CRP are used to evaluate the severity, but increasing knowledge about the biomarkers has elucidated the pathogenesis of NE. High plasma interleukin-6 levels are associated with clinically severe disease and can be used as a marker of severity [68]. High CRP as such does not indicate a severe form of NE, and, interestingly, high CRP may even be a protective factor for severe AKI in NE. Interestingly, CRP injection has been found protective in experimental immune-complex-mediated nephritis [69]. High levels of Gal-3BP have been detected in the acute stage of NE [70]. Furthermore, the levels correlate with disease severity, i.e., variables reflecting fluid retention and the length of hospital stay. Interestingly, the Gal-3BP level also correlates with increased complement activation [70]. These results suggest

that Gal-3BP could possess antiviral action by triggering an innate immune response via activation of the complement system. Additional biomarkers include elevated cerebrospinal fluid neopterin [71] and plasma B-type natriuretic peptide (BNP) [72].

Recent interesting additions to the list of biomarkers are glucosuria [73] and especially the plasma glucose concentration during the first few days after the onset of fever [74], which was associated with the severity of capillary leakage, thrombocytopenia, and inflammation in patients with acute PUUV infection. The effect on AKI was J-shaped. It is possible that a higher plasma glucose concentration is merely a sign of a more severe disease. However, plasma glucose may also influence the pathophysiological process of PUUV infection by damaging the vascular endothelium.

2.5. Perspectives

Notably, reinfections do not exist. Thus, hantavirus vaccines are a potential possibility, but no antiviral drugs or vaccines acceptable by “western” standards are currently used.

However, measures to counteract key events in pathobiology offer a promising strategy. Vascular leakage of endothelial cells (increased capillary permeability), not cell lysis or apoptosis, is a key element in the pathobiology of hantavirus disease. We have described the successful use of icatibant in two very severe cases of NE [75–77]. Icatibant is a synthetic polypeptide that acts as a selective antagonist for the bradykinin (BK) type 2 receptor, and it reduces increased vascular permeability and inhibits vasodilatation. BK is a potent vasodilator generated locally by endothelial cells from HMW kininogen by the kallikrein-kinin proteolytic system. BK is a nonapeptide (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) rapidly degraded by angiotensin-converting enzyme and carboxypeptidase and slowly by aminopeptidase. BK receptor 2 is constitutively expressed and participates in BK’s vasodilatory role. Icatibant is a nontoxic drug licensed for the treatment of acute episodes of hereditary angioedema, which can be life-threatening when swelling compromises the airways. Whether icatibant is useful in other hemorrhagic fevers remains to be seen. Interestingly, increased vascular permeability during experimental hantavirus infection can be prevented with drugs that block BK binding [78]. Icatibant, in fact, may be a useful therapy in various infections since adding it to standard care improved both COVID-19 pneumonia and mortality in a very recent proof-of-concept study [79].

3. Concluding Remarks

We conclude that the initial question “Why are the outcomes of a PUUV infection so varying?” remains, at least principally, unanswered. Multiple genetic factors appear to play a role. No differences in the virulence of the PUUV strains have been discovered, but they have also not been thoroughly studied thus far.

The pathogenesis of NE PUUV disease is complicated in many respects. Host immune and inflammatory mechanisms are probably important in the pathogenesis leading to the clinical symptoms. The incubation time is unusually long, and when clinical symptoms appear, the virus has already established a general infection in multiple tissues. This complicates the application of antiviral treatments. However, measures to counteract key events in pathobiology offer a promising strategy, as shown by the use of icatibant to counteract vascular leakage. Similar approaches are most welcome.

Author Contributions: Writing—original draft preparation, A.V.; writing—review and editing, T.S. (Teemu Smura), H.V., J.H., T.S. (Tarja Sironen), T.S. (Tomas Strandin), J.T., T.O., S.M., I.P. and J.M. All authors have read and agreed to the published version of the manuscript.

Funding: Our original work was recently supported by the Sigrid Jusélius Foundation (A.V., J.M., and J.H.), the Academy of Finland (T.St.), the Finnish Society of Sciences and Letters (T.Sm.), the Magnus Ehrnrooth Foundation (A.V.), and the Competitive State Research Financing of the Responsibility Area of Tampere University Hospital (J.M. and S.M.).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Vaheri, A.; Henttonen, H.; Mustonen, J. Hantavirus research in Finland: Highlights and perspectives. *Viruses* **2021**, *13*, 1452. [[CrossRef](#)] [[PubMed](#)]
2. Vaheri, A.; Strandin, T.; Hepojoki, J.; Sironen, T.; Henttonen, H.; Mäkelä, S.; Mustonen, J. Uncovering the mysteries of hantavirus infection. *Nat. Rev. Microbiol.* **2013**, *11*, 539–550. [[CrossRef](#)] [[PubMed](#)]
3. Vaheri, A.; Henttonen, H.; Voutilainen, L.; Mustonen, J.; Sironen, T.; Vapalahti, O. Hantavirus infections in Europe and their impact on public health. *Rev. Med. Virol.* **2013**, *23*, 35–49. [[CrossRef](#)]
4. Mustonen, J.; Mäkelä, S.; Outinen, T.; Laine, O.; Jylhävä, J.; Arstila, P.T.; Hurme, M.; Vaheri, A. The pathogenesis of nephropathia epidemica: New knowledge and unanswered questions. *Antivir. Res.* **2013**, *100*, 589–604. [[CrossRef](#)]
5. Jonsson, C.B.; Figueiredo, L.T.; Vapalahti, O. A global perspective on hantavirus ecology, epidemiology, and disease. *Clin. Microbiol. Rev.* **2010**, *23*, 412–441. [[CrossRef](#)]
6. Laenen, L.; Vergote, V.; Calisher, C.H.; Klempa, B.; Klingström, J.; Kuhn, J.H.; Maes, P. Hantaviridae: Current classification and future perspectives. *Viruses* **2019**, *11*, 788. [[CrossRef](#)] [[PubMed](#)]
7. Charbonnel, N.; Pagès, M.; Sironen, T.; Henttonen, H.; Vapalahti, O.; Mustonen, J.; Vaheri, A. Immunogenetic factors affecting susceptibility of humans and rodents to hantaviruses and the clinical course of hantaviral disease in humans. *Viruses* **2014**, *6*, 2214–2241. [[CrossRef](#)]
8. Voutilainen, L.; Sironen, T.; Tonteri, E.; Bäck, A.T.; Razzauti, M.; Karlsson, M.; Wahlström, M.; Niemimaa, J.; Henttonen, H.; Lundkvist, Å. Life-long shedding of Puumala hantavirus in wild bank voles (*Myodes glareolus*). *J. Gen. Virol.* **2015**, *96*, 1238–1247. [[CrossRef](#)]
9. Dabisch, P.A.; Biryukov, J.; Beck, K.; Boydston, J.A.; Sanjak, J.S.; Herzo, A.; Green, B.; Williams, G.; Yeage, J.; Bohannon, J.K.; et al. Serokonversion and fever are dose-dependent in a nonhuman primate model of inhalational COVID-19. *PLoS Pathog.* **2021**, *17*, e1009865. [[CrossRef](#)]
10. Klingström, J.; Plyusnin, A.; Vaheri, A.; Lundkvist, Å. Wild-type Puumala hantavirus infection induces cytokines, C-reactive protein, creatinine, and nitric oxide in cynomolgus macaques. *J. Virol.* **2002**, *76*, 444–449. [[CrossRef](#)]
11. Razzauti, M.; Plyusnina, A.; Sironen, T.; Henttonen, H.; Plyusnin, A. Analysis of Puumala hantavirus in a bank vole population in northern Finland: Evidence for co-circulation of two genetic lineages and frequent reassortment between wild-type strains. *J. Gen. Virol.* **2009**, *90*, 1923–1931. [[CrossRef](#)] [[PubMed](#)]
12. Lundkvist, Å.; Cheng, Y.; Brus Sjölander, K.; Niklasson, B.; Vaheri, A.; Plyusnin, A. Cell culture adaptation of Puumala hantavirus changes the infectivity for its natural reservoir, *Clethrionomys glareolus*, and leads to accumulation of mutants with altered genomic RNA S segment. *J. Virol.* **1997**, *71*, 9515–9523. [[CrossRef](#)]
13. Trowsdale, J.; Knight, J.C. Major histocompatibility complex genomics and human disease. *Genom. Hum. Genet.* **2013**, *14*, 301–323. [[CrossRef](#)]
14. Mustonen, J.; Partanen, J.; Kanerva, M.; Pietilä, K.; Vapalahti, O.; Pasternack, A.; Vaheri, A. Genetic susceptibility to severe course of nephropathia epidemica caused by Puumala hantavirus. *Kidney Int.* **1996**, *49*, 217–221. [[CrossRef](#)]
15. Plyusnin, A.; Hörling, J.; Kanerva, M.; Mustonen, J.; Cheng, Y.; Partanen, J.; Vapalahti, O.; Kukkonen, S.K.; Niemimaa, J.; Henttonen, H.; et al. Puumala hantavirus genome in patients with nephropathia epidemica: Correlation of PCR positivity with HLA haplotype and link to viral sequences in local rodents. *J. Clin. Microbiol.* **1997**, *35*, 1090–1096. [[CrossRef](#)] [[PubMed](#)]
16. Mustonen, J.; Partanen, J.; Kanerva, M.; Pietilä, K.; Vapalahti, O.; Pasternack, A.; Vaheri, A. Association of HLA-B27 with benign clinical course of nephropathia epidemica caused by Puumala hantavirus. *Scand. J. Immunol.* **1998**, *47*, 277–279. [[CrossRef](#)] [[PubMed](#)]
17. Korva, M.; Saksida, A.; Kunilo, S.; Jeras, B.V.; Avsic-Zupanc, T. HLA-associated hemorrhagic fever with renal syndrome disease progression in Slovenian patients. *Clin. Vacc. Immunol.* **2011**, *18*, 1435–1440. [[CrossRef](#)]
18. The Mhc sequencing consortium. Complete sequence and genemap of a human major histocompatibility complex. *Nature* **1999**, *401*, 921–923. [[CrossRef](#)]
19. Kanerva, M.; Vaheri, A.; Mustonen, J.; Partanen, J. High-producer allele of tumour necrosis factor-alpha is part of the susceptibility MHC haplotype in severe Puumala virus-induced nephropathia epidemica. *Scand. J. Inf. Dis.* **1998**, *30*, 532–534.
20. Temonen, M.; Mustonen, J.; Helin, H.; Pasternack, A.; Vaheri, A.; Holthofer, H. Cytokines, adhesion molecules, and cellular infiltration in nephropathia epidemica kidneys: An immunohistochemical study. *Clin. Immunol. Immunopath.* **1996**, *78*, 47–55. [[CrossRef](#)]
21. Mäkelä, S.; Mustonen, J.; Ala-Houhala, I.; Hurme, M.; Partanen, J.; Vapalahti, O.; Vaheri, A.; Pasternack, A. Human leukocyte antigen-B8-DR3 is a more important risk factor for severe Puumala hantavirus infection than the tumor necrosis factor-a(-308) G/A polymorphism. *J. Infect. Dis.* **2002**, *186*, 843–846. [[CrossRef](#)]
22. Collins, A.R. Human coronavirus OC43 interacts with major histocompatibility complex class I molecules at the cell surface to establish infection. *Immunol. Investig.* **1994**, *23*, 313–321. [[CrossRef](#)] [[PubMed](#)]
23. Alper, C.A.; Awdeh, Z.; Yunis, E.J. Conserved, extended MHC haplotypes. *Exp. Clin. Immunogenet.* **1992**, *9*, 58–71.
24. Paakkala, A.; Mustonen, J.; Viander, M.; Huhtala, H.; Pasternack, A. Complement activation in nephropathia epidemica caused by Puumala hantavirus. *Clin. Nephrol.* **2000**, *53*, 27–32.
25. Sane, J.; Laine, O.; Mäkelä, S.; Paakkala, A.; Jarva, H.; Mustonen, J.; Vapalahti, O.; Meri, S.; Vaheri, A. Complement activation in Puumala hantavirus infection correlates with disease severity. *Ann. Med.* **2012**, *44*, 468–475. [[CrossRef](#)]

26. Sironen, T.; Sane, J.; Lokki, M.-L.; Meri, S.; Andersson, L.C.; Hautala, T.; Kauma, H.; Vuorinen, S.; Rasmuson, J.; Evander, M.; et al. Fatal Puumala hantavirus disease: Involvement of complement activation and vascular leakage in the pathobiology. *Open Forum Infect. Dis.* **2017**, *4*, ofx229. [[CrossRef](#)]
27. Paakkala, A.; Mäkelä, S.; Hurme, M.; Partanen, J.; Huhtala, H.; Mustonen, J. Association of chest radiography findings with host-related genetic factors in patients with nephropathia epidemica. *Scand. J. Infect. Dis.* **2008**, *40*, 254–258. [[CrossRef](#)]
28. Mäkelä, S.; Hurme, M.; Ala-Houhala, I.; Mustonen, J.; Koivisto, A.-M.; Partanen, J.; Vapalahti, O.; Vaheri, A.; Pasternack, A. Polymorphism of the cytokine genes in hospitalized patients with Puumala hantavirus infection. *Nephrol. Dial. Transplant.* **2001**, *16*, 1368–1373. [[CrossRef](#)] [[PubMed](#)]
29. Laine, O.; Joutsu-Korhonen, L.; Mäkelä, S.; Mikkelsen, J.; Pessi, T.; Tuomisto, S.; Huhtala, H.; Libraty, D.; Vaheri, A.; Karhunen, P.; et al. Polymorphisms of PAI-1 and platelet GP Ia may associate with impairment of renal function and thrombocytopenia in Puumala hantavirus infection. *Thromb. Res.* **2012**, *129*, 611–615. [[CrossRef](#)]
30. Koskela, S.; Laine, O.; Mäkelä, S.; Pessi, T.; Tuomisto, S.; Huhtala, H.; Karhunen, P.J.; Pörsti, I.; Mustonen, J. Endothelial nitric oxide synthase G894T polymorphism associates with disease severity in Puumala hantavirus infection. *PLoS ONE* **2015**, *10*, e0142872. [[CrossRef](#)]
31. Bharadwaj, M.; Nofchissey, R.; Goade, D.; Koster, F.; Hjelle, B. Humoral immune responses in the hantavirus cardiopulmonary syndrome. *J. Infect. Dis.* **2000**, *182*, 43–48. [[CrossRef](#)]
32. Iheozor-Ejiofor, R.; Vapalahti, K.; Sironen, T.; Levanov, L.; Hepojoki, J.; Lundkvist, Å.; Mäkelä, S.; Vaheri, A.; Mustonen, J.; Plyusnin, A.; et al. Neutralizing antibody titers in hospitalized patients with acute Puumala orthohantavirus infection do not associate with disease severity. *Viruses* **2022**, *14*, 901. [[CrossRef](#)]
33. Penttinen, K.; Lähdevirta, J.; Kekomäki, R.; Ziola, B.; Salmi, A.; Hautanen, A.; Lindström, P.; Vaheri, A.; Brummer-Korvenkontio, M.; Wager, O. Circulating immune complexes, immunoglobulins and antiglobulins in nephropathia epidemica. *J. Infect. Dis.* **1981**, *143*, 15–21. [[CrossRef](#)]
34. Wangel, A.G.; Temonen, M.; Brummer-Korvenkontio, M.; Vaheri, A. Anti-endothelial cell antibodies in nephropathia epidemica and other viral diseases. *Clin. Exp. Immunol.* **1992**, *90*, 13–17. [[CrossRef](#)] [[PubMed](#)]
35. Tarvainen, M.; Mäkelä, S.; Mustonen, J.; Jaatinen, P. Autoimmune polyendocrinopathy and hypophysitis after Puumala hantavirus infection. *Endocrinol. Diabetes Metab. Case Rep.* **2016**, *2016*, 16-0084. [[CrossRef](#)] [[PubMed](#)]
36. Tuuminen, T.; Kekäläinen, E.; Mäkelä, S.; Ala-Houhala, I.; Ennis, F.A.; Hedman, K.; Mustonen, J.; Vaheri, A.; Arstila, T.P. Human CD8+ T cell memory generation in Puumala hantavirus infection occurs after the acute phase and is associated with boosting of EBV-specific CD8+ memory T cells. *J. Immunol.* **2007**, *179*, 1988–1995. [[CrossRef](#)]
37. Lamponen, T.; Hetemäki, L.; Niemi, H.J.; Jarva, H.; Mäkelä, S.M.; Mustonen, J.; Vaheri, A.; Arstila, T.P. Heterologous boosting of nonrelated toxoid immunity during acute Puumala hantavirus infection. *Vaccine* **2021**, *39*, 1818–1825. [[CrossRef](#)]
38. Hepojoki, J.; Cabrera, L.; Hepojoki, S.; Bellomo, C.; Kareinen, L.; Andersson, L.C.; Vaheri, A.; Mäkelä, S.; Mustonen, J.; Vapalahti, O.; et al. Hantavirus infection-induced B cell activation elevates free light chain levels in circulation. *PLoS Pathog.* **2021**, *17*, e1009843. [[CrossRef](#)]
39. Klingström, J.; Granath, F.; Ekblom, A.; Björkström, N.K.; Ljunggren, H.G. Increased risk for lymphoma following hemorrhagic fever with renal syndrome. *Clin. Inf. Dis.* **2014**, *59*, 1130–1132. [[CrossRef](#)] [[PubMed](#)]
40. Kontkanen, M.; Puustjärvi, T.; Kauppi, P.; Lähdevirta, J. Ocular characteristics in nephropathia epidemica or Puumala virus infection. *Acta Ophthalmol. Scand.* **1996**, *74*, 621–625. [[CrossRef](#)]
41. Alexeyev, O.A.; Morozov, V.G. Neurological manifestations of hemorrhagic fever with renal syndrome caused by Puumala virus: Review of 811 cases. *Clin. Infect. Dis.* **1995**, *20*, 255–258. [[CrossRef](#)]
42. Hautala, T.; Mähönen, S.-M.; Sironen, T.; Hautala, N.; Pääkkö, E.; Karttunen, A.; Salmela, P.I.; Ilonen, J.; Vainio, O.; Glumoff, V.; et al. Central nervous system related symptoms and findings are common in acute Puumala hantavirus infection. *Ann. Med.* **2010**, *42*, 344–351. [[CrossRef](#)] [[PubMed](#)]
43. Hautala, N.; Kauma, H.; Vapalahti, O.; Mähönen, S.-M.; Vainio, O.; Vaheri, A.; Hautala, T. Prospective study on ocular findings in acute Puumala hantavirus infection in hospitalised patients. *Brit. J. Ophthalmol.* **2011**, *95*, 559–562. [[CrossRef](#)]
44. Hautala, T.; Hautala, N.; Mähönen, S.-M.; Sironen, T.; Pääkkö, E.; Karttunen, A.; Salmela, P.I.; Vainio, O.; Rytty, S.; Plyusnin, A.; et al. Young male patients are at elevated risk of developing serious central nervous system complications during acute Puumala hantavirus infection. *BMC Infect. Dis.* **2011**, *11*, 217. [[CrossRef](#)] [[PubMed](#)]
45. Hautala, N.; Kauma, H.; Rajaniemi, S.-M.; Sironen, T.; Vapalahti, O.; Pääkkö, E.; Karttunen, A.; Ilonen, J.; Rytty, S.; Vainio, O.; et al. Signs of general inflammation and kidney function are associated with the ocular features of acute Puumala hantavirus infection. *Scand. J. Infect. Dis.* **2012**, *44*, 956–962. [[CrossRef](#)] [[PubMed](#)]
46. Hautala, N.; Partanen, T.; Kubin, A.-M.; Kauma, H.; Hautala, T. Central nervous system and ocular manifestations in Puumala hantavirus infection. *Viruses* **2021**, *13*, 1040. [[CrossRef](#)]
47. Partanen, I.; Chen, J.; Lehtonen, J.; Kuismin, O.; Rusanen, H.; Vapalahti, O.; Vaheri, A.; Anttila, V.J.; Bode, M.; Hautala, N.; et al. Heterozygous TLR3 mutation in patients with hantavirus encephalitis. *J. Clin. Immunol.* **2020**, *40*, 1156–1162. [[CrossRef](#)]
48. Mäkelä, S.; Jaatinen, P.; Miettinen, M.; Salmi, J.; Ala-Houhala, I.; Huhtala, H.; Hurme, M.; Pörsti, I.; Vaheri, A.; Mustonen, J. Hormonal deficiencies during and after Puumala hantavirus infection. *Eur. J. Clin. Microbiol.* **2010**, *29*, 705–713. [[CrossRef](#)]
49. Partanen, T.; Koivikko, M.; Leisti, P.; Salmela, P.; Pääkkö, E.; Karttunen, A.; Sintonen, H.; Risteli, L.; Hautala, N.; Vapalahti, O.; et al. Long-term hormonal follow-up after human Puumala hantavirus infection. *Clin. Endocrinol.* **2018**, *84*, 85–91. [[CrossRef](#)]

50. Tarvainen, M.; Mäkelä, S.; Laine, O.; Pörsti, I.; Risku, S.; Niemelä, O.; Mustonen, J.; Jaatinen, P. Hormonal defects are common during Puumala hantavirus infection and associate with disease severity and biomarkers of altered haemostasis. *Viruses* **2021**, *13*, 1818. [[CrossRef](#)]
51. Mustonen, J.; Huttunen, N.-P.; Brummer-Korvenkontio, M.; Vaheri, A. Clinical picture of nephropathia epidemica in children. *Acta Paediatr.* **1994**, *83*, 526–529. [[CrossRef](#)] [[PubMed](#)]
52. Huttunen, N.-P.; Mäkelä, S.; Pokka, T.; Mustonen, J.; Uhari, M. Systematic literature review of symptoms, signs and severity of serologically confirmed nephropathia epidemica in paediatric and adult patients. *Scand. J. Infect. Dis.* **2011**, *43*, 405–410. [[CrossRef](#)] [[PubMed](#)]
53. Mustonen, J.; Huttunen, N.-P.; Partanen, J.; Baer, M.; Paakkala, A.; Vapalahti, O.; Uhari, M. Human leukocyte antigens DRB1*03 in pediatric patients with nephropathia epidemica caused by Puumala hantavirus. *Pediatr. Infect. Dis.* **2004**, *23*, 959–961. [[CrossRef](#)] [[PubMed](#)]
54. Klein, S.L.; Marks, M.A.; Li, W.; Glass, G.E.; Fang, L.Q.; Ma, J.Q.; Cao, W.C. Sex differences in the incidence and case fatality rates from hemorrhagic fever with renal syndrome in China, 2004–2008. *Clin. Infect. Dis.* **2011**, *52*, 1414–1421. [[CrossRef](#)]
55. Krautkrämer, E.; Grouls, S.; Urban, E.; Schnitzler, P.; Zeier, M. No gender-related differences in the severity of nephropathia epidemica, Germany. *BMC Infect. Dis.* **2013**, *13*, 457. [[CrossRef](#)]
56. Tietäväinen, J.; Laine, O.; Mäkelä, S.; Huhtala, H.; Pörsti, I.; Vaheri, A.; Mustonen, J. ABO and Rhesus blood groups in acute Puumala hantavirus infection. *Viruses* **2021**, *13*, 2271. [[CrossRef](#)]
57. Fevola, C.; Forbes, K.M.; Mäkelä, S.; Putkuri, N.; Hauffe, H.C.; Kallio-Kokko, H.; Mustonen, J.; Jääskeläinen, A.J.; Vaheri, A. Lymphocytic choriomeningitis, Ljungan and orthopoxvirus seroconversions in patients hospitalized due to acute Puumala hantavirus infection. *J. Clin. Virol.* **2016**, *84*, 48–52. [[CrossRef](#)]
58. Tervo, L.; Mäkelä, S.; Syrjänen, J.; Huttunen, R.; Rimpelä, A.; Huhtala, H.; Vapalahti, O.; Vaheri, A.; Mustonen, J. Smoking is associated with aggravated kidney injury in Puumala hantavirus-induced haemorrhagic fever with renal syndrome. *Nephrol. Dial. Transpl.* **2015**, *30*, 1693–1698. [[CrossRef](#)]
59. Kitterer, D.; Segerer, S.; Dippon, J.; Alschner, M.D.; Braun, N.; Latus, J. Smoking is a risk factor for severe acute kidney injury in hantavirus-induced nephropathia epidemica. *Nephron* **2016**, *134*, 89–94. [[CrossRef](#)]
60. Latronico, F.; Mäki, S.; Rissanen, H.; Ollgren, J.; Lyytikäinen, O.; Vapalahti, O.; Sane, J. Population-based seroprevalence of Puumala hantavirus in Finland: Smoking as a risk factor. *Epidemiol. Infect.* **2018**, *146*, 367–371. [[CrossRef](#)]
61. Tervo, L.; Outinen, T.K.; Mäkelä, S.; Mustalahti, J.; Huhtala, H.; Pörsti, I.; Syrjänen, J.; Mustonen, J.T.; Niemelä, O. The presence of intraperitoneal, retroperitoneal and pleural fluid in acute Puumala hantavirus infection. *Viruses* **2022**, *14*, 500. [[CrossRef](#)]
62. Outinen, T.K.; Mäkelä, S.; Pörsti, I.; Vaheri, A.; Mustonen, J. Severity biomarkers in Puumala hantavirus infection. *Viruses* **2022**, *14*, 45. [[CrossRef](#)]
63. Outinen, T.K.; Mäkelä, S.; Clement, J.; Paakkala, A.; Pörsti, I.; Mustonen, J. Community acquired severe acute kidney injury caused by hantavirus-induced hemorrhagic fever with renal syndrome has a favorable outcome. *Nephron* **2015**, *130*, 182–190. [[CrossRef](#)]
64. Mäkelä, S.; Ala-Houhala, I.; Mustonen, J.; Koivisto, A.-M.; Kouri, T.; Turjanmaa, V.; Vapalahti, O.; Vaheri, A.; Pasternack, A. Renal function and blood pressure five years after Puumala virus-induced nephropathy. *Kidney Int.* **2000**, *58*, 1711–1718. [[CrossRef](#)] [[PubMed](#)]
65. Miettinen, M.H.; Mäkelä, S.M.; Ala-Houhala, I.O.; Huhtala, H.S.A.; Kööbi, T.; Vaheri, A.; Pasternack, A.I.; Pörsti, I.H.; Mustonen, J.T. Ten-year prognosis of Puumala hantavirus-induced acute interstitial nephritis. *Kidney Int.* **2006**, *69*, 2043–2048. [[CrossRef](#)]
66. Miettinen, M.H.; Mäkelä, S.M.; Ala-Houhala, I.O.; Huhtala, H.S.A.; Hurme, M.A.; Kööbi, T.; Partanen, J.A.; Pasternack, A.I.; Vaheri, A.; Pörsti, I.H.; et al. The severity of acute Puumala hantavirus infection does not predict the long-term outcome of patients. *Nephron Clin. Pract.* **2010**, *116*, 89–94. [[CrossRef](#)] [[PubMed](#)]
67. Mustonen, J.; Vaheri, A.; Pörsti, I.; Mäkelä, S. Long-term consequences of Puumala hantavirus infection. *Viruses* **2022**, *14*, 598. [[CrossRef](#)]
68. Outinen, T.; Mäkelä, S.; Ala-Houhala, I.; Huhtala, H.; Hurme, M.; Paakkala, A.; Pörsti, I.; Syrjänen, J.; Mustonen, J. The severity of Puumala hantavirus induced nephropathia epidemica can be better evaluated using plasma interleukin-6 than C-reactive protein determinations. *BMC Infect. Dis.* **2010**, *10*, 132–135. [[CrossRef](#)]
69. Rodriguez, W.; Mold, C.; Kataranovski, M.; Hutt, J.A.; Marnell, L.L.; Verbeek, J.S.; Du Clos, T.W. C-reactive protein-mediated suppression of nephrotoxic nephritis: Role of macrophages, complement, and Fc gamma receptors. *J. Immunol.* **2007**, *178*, 530–538. [[CrossRef](#)]
70. Hepojoki, J.; Strandin, T.; Hetzel, U.; Sironen, T.; Klingström, J.; Sane, J.; Mäkelä, S.; Mustonen, J.; Meri, S.; Lundkvist, Å.; et al. Acute hantavirus infection induces galectin-3-binding protein. *J. Gen. Virol.* **2014**, *95*, 2356–2364. [[CrossRef](#)] [[PubMed](#)]
71. Hautala, T.; Partanen, T.; Sironen, T.; Rajaniemi, S.M.; Hautala, N.; Vainio, O.; Vapalahti, O.; Kauma, H.; Vaheri, A. Elevated cerebrospinal fluid neopterin concentration is associated with disease severity in acute Puumala hantavirus infection. *Clin. Dev. Immunol.* **2013**, *2013*, 634632. [[CrossRef](#)]
72. Rajaniemi, S.R.; Hautala, N.; Sironen, T.; Vainio, O.; Vapalahti, O.; Vaheri, A.; Vuolteenaho, O.; Ruskoaho, H.; Kauma, H.; Hautala, T. Plasma B-type natriuretic peptide (BNP) in acute Puumala hantavirus infection. *Ann. Med.* **2014**, *46*, 38–43. [[CrossRef](#)]
73. Tietäväinen, J.; Mantula, P.; Outinen, T.; Huhtala, H.; Pörsti, I.H.; Niemelä, O.; Vaheri, A.; Mäkelä, S.; Mustonen, J. Glucosuria predicts the severity of Puumala hantavirus infection. *Kidney Int. Rep.* **2019**, *4*, 1296–1303. [[CrossRef](#)]

74. Tietäväinen, J.; Mäkelä, S.; Huhtala, H.; Pörsti, I.H.; Strandin, T.; Vaheri, A.; Mustonen, J. The clinical presentation of Puumala hantavirus induced hemorrhagic fever with renal syndrome is related to plasma glucose concentration. *Viruses* **2021**, *13*, 1177. [[CrossRef](#)] [[PubMed](#)]
75. Antonen, J.; Leppänen, I.; Tenhunen, J.; Arvola, P.; Mäkelä, S.; Vaheri, A.; Mustonen, J. A severe case of Puumala hantavirus infection successfully treated with bradykinin-receptor antagonist icatibant. *Scand. J. Infect. Dis.* **2013**, *45*, 494–496. [[CrossRef](#)] [[PubMed](#)]
76. Laine, O.; Leppänen, I.; Koskela, S.; Antonen, J.; Mäkelä, S.; Sinisalo, M.; Vaheri, A.; Mustonen, J. Severe Puumala infection in a patient with a lymphoproliferative disease treated with icatibant. *Infect. Dis.* **2015**, *47*, 107–111. [[CrossRef](#)] [[PubMed](#)]
77. Vaheri, A.; Strandin, T.; Jääskeläinen, A.J.; Vapalahti, O.; Jarva, H.; Lokki, M.-L.; Antonen, J.; Leppänen, I.; Mäkelä, S.; Meri, S.; et al. Pathophysiology of a severe case of Puumala hantavirus infection treated with bradykinin receptor antagonist icatibant. *Antivir. Res.* **2014**, *111*, 23–25. [[CrossRef](#)]
78. Taylor, S.L.; Wahl-Jensen, V.; Copeland, A.M.; Jahrling, P.B.; Schmaljohn, C.S. Endothelial cell permeability during hantavirus infection involves factor XII-dependent increased activation of the kallikrein-kinin system. *PLoS Pathog.* **2013**, *9*, e1003470. [[CrossRef](#)] [[PubMed](#)]
79. Malchair, P.; Giol, J.; García, V.; Rodríguez, O.; Ruibal, J.C.; Zarauza, A.; Llopis, F.; Matellán, L.; Bernal, T.; Solís, B.; et al. Three-day icatibant on top of standard care in patients with coronavirus disease-2019 pneumonia (ICAT-COVID): A randomized, open-label, phase 2, Proof-of-concept trial. *Clin. Infect. Dis.* **2023**, ciac984, ahead of print. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.